Colchicine is well known drug for the treatment of acute gout. Recently, it has also been used in the management of COVID-19 patients. The aim of current study is to find out the role of colchicine in COVID-19 patients. The relevant studies were searched in PubMed/Medline, Google scholar and clinical trail.gov.com till inception and sorted based on the inclusion and exclusion criteria. The quality assessment of studies were done using Newcastle Ottawa Quality Assessment Scale. The pooled estimate was calculated as odd ratio and pooled prevalence with 95% confidence interval. A random effect model was used and publication bias was assessed qualitatively by trim and fill method. Out of 38 studies, a total of 6 studies were found relevant for the analysis containing 1146 patients (705 males and 441 females). The pooled odd ratio was found to be 0.35 [0.23, 0.53] which indicate significance reduction of mortality in colchicine group as compared to non-colchicine group. The pooled prevalence of the patients treated with colchicine were found to be significant [0.11(0.03, 0.24)]. The heterogeneity among studies was also found to be low (I2 = 11%). However, funnel plot has indicated the involvement of publication bias [Egger: bias = 10.168291 (95% CI = 5.042044 to 15.294537) P = 0.0053]. Colchicine might be helpful in reduction of mortality in the management of COVID-19 patients. However, further studies are required to confirm its exact role.
2 March 2023 in Journal of Oncology Pharmacy Practice
Purpose: In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods: The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results: In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion: We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.
21 July 2022 in SN Comprehensive Clinical Medicine
Nanofiber, a novel approach in tissue engineering and regenerative medicine, emphasizes versatility in structure, drug entrapment capabilities, and advanced fabrication techniques that architect a biomimetic scaffold which supports tissue repair and regeneration. Due to the extensive surface area, controlled porosity, adherence to the cells and correspondence with the biological scaffold, nanofiber involves itself in optimal cell proliferation and differentiation. This nanofiber-driven approach prospects other designing methods (such as electrospinning), surface modification, and the incorporation of active ingredients to improve therapeutic responses. The promising objective for the management of healing wounds, bone and cartilage regeneration, normal tissue engineering, and advanced drug delivery emerges as the translational approach of nanofiber mats in novel regenerative medicine.